Camizestrant + CDK 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) vs AI + CDK 4/6 inhibitor

2026-05-22 — AstraZeneca announced it will present extensive oncology and rare disease data at the ASCO Annual Meeting (May 29–June 2, 2026), with more than 85 abstracts covering 10 approved and 13 potential new medicines (including 25 oral presentations). Key Phase III highlights include EMERALD-3 (IMFINZI + IMJUDO ± lenvatinib with TACE in unresectable, embolization-eligible hepatocellular carcinoma), SERENA-6 (camizestrant + CDK4/6 inhibitors in 1L HR+/HER2− advanced breast cancer with emergent ESR1 mutation, including final PFS2 and ctDNA clearance data), TROPION-Breast02 (DATROWAY in 1L metastatic TNBC not eligible for PD-1/PD-L1 inhibitors), DESTINY-Breast09 (ENHERTU + pertuzumab in 1L HER2+ metastatic breast cancer; exploratory outcomes by response), and POTOMAC (IMFINZI + BCG in high-risk NMIBC; 5-year overall survival and patient-reported outcomes). Rare disease: CARES Phase III will report clinically meaningful benefit for anselamimab (Alexion) in AL amyloidosis, including κ/λ subgroup analyses. AstraZeneca noted collaboration with Daiichi Sankyo on ENHERTU and DATROWAY.